Moore Paul Andrew, the Chief Scientific Officer of Zymeworks Inc., has made notable stock transactions that could influence investor sentiment regarding the company. On November 13, 2026, he reported acquiring 25,000 shares of Zymeworks and selling a total of 25,741 shares. These transactions were filed with the SEC on November 16, 2026.
The significance of these transactions lies in their potential to reflect the confidence of company executives in Zymeworks' future prospects. Given the competitive nature of the pharmaceutical preparations industry, such movements by key personnel can impact how investors view the company's stability and growth potential.
Background
Zymeworks Inc. is a company incorporated in Delaware that operates within the pharmaceutical preparations sector. The company is listed under the CIK number 0001937653 and has been involved in various filings, including recent transactions that highlight its activities in the market.
What the Filing Says
The filing indicates that Moore Paul Andrew acquired 25,000 shares of common stock at a price of $5.82 per share. Additionally, he disposed of shares in multiple transactions, with sales priced between $25.95 and $26.21 per share. Following these transactions, he holds a total of 73,497 shares.
Impact
The reported transactions may affect investor confidence in Zymeworks, particularly as they come from a high-ranking officer. Such activities can signal to the market the executive's belief in the company's future performance and stability.
What's Next
The filing does not specify what happens next regarding these transactions or any further actions from the company.
Read Next
Kaltenbach acquires 534 shares in Mettler Toledo
Keller Gerry Acquires Shares in Mettler Toledo
CFO Shawn Vadala acquires 176 shares in Mettler Toledo
Eli Samaha discloses sale of 9.2 million Theravance shares
Davion Healthcare to Acquire Independence Care Network
Tompkins Financial updates on conference participation





